Therapeutic Antibodies

#Antibodies #Bispecific Antibodies #Interview #Oncology #Therapeutic Antibodies

Dual-targeted antibody innovations for cancer treatment

David Epstein, Chair & Chief Executive Officer of Ottimo Pharma, speaks to Megan Thomas about innovation in therapeutic antibody development, in the context of the company’s accelerated development of a novel PD1/VEGFR2 bifunctional antibody planned to enter the clinic in 2025, designed as a dual-pathway, single agent, IgG therapy targeting… Read More

#Cancer Research #Exclusive Content

Monoclonal antibodies
#CSL #European Commission #Monoclonal antibodies #Rare disease

EC approves antibody to prevent hereditary angioedema attacks

The European Commission (EC) has approved Andembry (garadacimab), the only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.  Andembry inhibits plasma protein factor XIIa, which initiates the cascade of events leading to angioedema at various sites… Read More

#News #Regulatory

#Absci #AI / data analytics / healthtech / informatics #Antibodies #Artificial intelligence (AI) #Drug discovery #Drug targets #Interview #Machine learning

New podcast: The continued evidence of AI’s drug discovery value

This is the latest episode of the free DDW narrated podcast, titled “The continued evidence of AI’s drug discovery value”, which covers two articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “How generative AI could improve drug discovery” and “Can… Read More

#News

Novartis head office
#Anthos Therapeutics #Cardiovascular disease #Mergers and acquisitions #Monoclonal antibodies #Novartis

Novartis acquires Anthos Therapeutics for $925 million

Novartis has agreed to acquire Anthos Therapeutics, a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway.  Abelacimab is currently in Phase III development, with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillation.  Novartis will make an… Read More

#Business & Investment #News #Trending News

European Union and African Union flags
#Biologics #Collaboration #Immunology / Virology & Vaccines #mRNA-based vaccines #RNA

African European alliance to advance RNA-based vaccines

A new African European collaboration aims to develop the first ever digital-to-biologics, end-to-end mRNA production platform, focusing on nucleic acid-based vaccines and therapeutics, including mRNA and saRNA vaccines.  A Memorandum of Understanding was signed by Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences during the… Read More

#News

#Antibodies #Autoimmune disease #Collaboration #FcR Therapeutics #Grifols #Nanobodies

Partners to target autoimmune Fc receptors using nanobodies

Grifols and biotechnology startup, FcR Therapeutics, have agreed to collaborate on recombinant nanobodies to treat autoimmune diseases.  The nanobodies, which are small highly specialised antibody fragments, would act to restrain or inhibit the activity of certain Fc receptors (FcR), naturally occurring proteins found on the surface of immune cells that… Read More

#Business & Investment #News

Mosquito
#Immunology / Virology & Vaccines #Monoclonal antibodies #National Institutes of Health (NIH) #Phase II trial

Phase II trial will test monoclonal antibody for dengue

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment for the effects of dengue, a mosquito-borne viral disease.   The study is supported by NIH’s National Institute of Allergy and Infectious Diseases (NIAID).  It will test the ability of… Read More

#News

#Financing #Helicore Biopharma #Monoclonal antibodies #Obesity #Weight loss

Obesity drug developer emerges from stealth with a $65m financing

Helicore Biopharma has announced its emergence from stealth mode with $65 million in Series A financing, co-led by founding investor Versant Ventures and by OrbiMed.  The company is focused on the discovery and development of first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions.  Helicore’s most advanced asset,… Read More

#Business & Investment #News

#Antibody drug conjugate (ADC) #Bispecific Antibodies #Breast cancer #Oncology #Solid tumours

This week in drug discovery (20-24 January) 

News round-up for 20-24 January by DDW Senior Digital Content Editor Diana Spencer. In the same week that Phesi revealed that breast cancer is the most studied disease for the fourth year in a row, there have been a number of breakthroughs in the treatment of solid tumours,… Read More

#News

The European Medicines Agency in Amsterdam
#European Commission #Monoclonal antibodies #Myeloma #Oncology #Sanofi

EU extends Sarclisa use to newly diagnosed multiple myeloma

Following the adoption of a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has now approved Sanofi’s monoclonal antibody Sarclisa (isatuximab).  It is approved in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult… Read More

#News #Regulatory

Non-small cell lung cancer
#Bispecific Antibodies #European Commission #Johnson & Johnson #Non-small cell lung cancer (NSCLC) #Oncology

Bispecific antibody combo for NSCLC could extend life by a year

The European Commission (EC) has approved a Marketing Authorisation (MA) for Lazcluze (lazertinib), in combination with Rybrevant (amivantamab).  It is approved for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or exon 21 L858R (L858R)… Read More

#News #Regulatory

Bispecific antibodies
#Bispecific Antibodies #Bispecific therapeutics #Daiichi Sankyo #Oncology #Partnership #Solid tumours

Partners invite proposals for multi-functional biologics research

Daiichi Sankyo and German research institute BioMed X have agreed a new partnership to advance the development of bi- and multi-specific biologics for treating solid tumours.  The new project, entitled ‘New Strategies for Targeting of Solid Tumours with Multi-Specific Biologics (MTT; Multi-Specific Targeting of Tumours)’, will be hosted at the… Read More

#Business & Investment #News

Business financing
#Asthma #Financing #Immunology #Monoclonal antibodies #Windward Bio

Windward Bio launches with $200 million

Windward Bio, a clinical-stage, drug development company focused on advanced immunological diseases, has announced its official launch.   OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities lead the Series A financing of $200 million, with the co-investment of SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal… Read More

#Business & Investment #News #Start-up Zone

Tau proteins
#Alzheimer's #Fast Track designation #FDA #Johnson & Johnson #Monoclonal antibodies #Neuroscience

Tau-directed mAb receives US FDA fast track designation

The US Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb).  The therapy from Johnson & Johnson is being investigated to treat patients with early Alzheimer’s disease (AD) in the Phase IIb AuTonomy study.   It has shown potential in targeting disease-associated… Read More

#News #Regulatory

Mosquito
#Antibodies #Immunology / Virology & Vaccines #Malaria #Monoclonal antibodies #National Institutes of Health (NIH)

Researchers discover novel class of anti-malaria antibodies

A novel class of antibodies that binds to a previously untargeted portion of the malaria parasite could lead to new prevention methods, according to a study from researchers at the National Institutes of Health (NIH) published in Science.   Of the five species of… Read More

#News

IgE antibodies
#Antibodies #Bifunctional medicine #Cancer research #Funding #Investment #Ottimo Pharma

Bifunctional medicines to extend the lives of cancer patients

Ottimo Pharma has completed a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumour indications, in both IV and SC forms as well as a pipeline of follow-on bifunctional assets. The round was led… Read More

#Business & Investment #Cancer Research #Editor's Choice #News